{"id":"W2091394897","doi":"10.1007/s10637-006-9009-4","title":"A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia","year":2006,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Cancer Institute","keywords":"Medicine; Bortezomib; Tolerability; Internal medicine; Phases of clinical research; Adverse effect; Metastatic Urothelial Carcinoma; Population; Cancer; Clinical trial; Chemotherapy; Response Evaluation Criteria in Solid Tumors; Oncology; Surgery; Gastroenterology; Multiple myeloma; Urothelial carcinoma; Bladder cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002692248,0.001674351,0.001677328,0.0006765217,0.0005997699,0.001061915,0.0009356166,0.001736879,0.005108596],"category_scores_gemma":[0.001320544,0.000728862,0.001386721,0.0005506806,0.0009829642,0.0007134887,0.0004614713,0.003658113,0.0009123938],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009011307,"about_ca_system_score_gemma":0.001987223,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001559687,"about_ca_topic_score_gemma":0.003153107,"domain_scores_codex":[0.9993082,0.00041569,0.00001880676,0.00008087496,0.00006223987,0.0001142386],"domain_scores_gemma":[0.9987174,0.0002416339,0.0001311724,0.00006871216,0.00005939445,0.0007816167],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8036508,0.03321129,0.004852248,0.0006933801,0.0009365618,0.0003503991,0.0002566409,0.002186507,0.0265478,0.0006594706,0.01290251,0.1137525],"study_design_scores_gemma":[0.8648313,0.1239793,0.005410961,0.00002975745,0.000251846,0.0001544726,0.00002754322,0.0006742713,0.001525837,0.0002777518,0.002812791,0.00002412632],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9768531,0.006265402,0.00109106,0.002842482,0.0006029355,0.005264013,0.002357648,0.0001838121,0.004539566],"genre_scores_gemma":[0.9679248,0.005331824,0.003642209,0.003665011,0.0005827635,0.005054173,0.005478959,0.00007741941,0.008242881],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005108596,"threshold_uncertainty_score":0.01708996,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01672705479726409,"score_gpt":0.2777420946554259,"score_spread":0.2610150398581618,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}